Ask AI
ProCE Banner Activity

Experts Discuss Novel Approaches to First-line Therapy for HER2-Positive Metastatic Breast Cancer

Podcast Episodes

Listen to Erika Hamilton, MD, FASCO, and Ian Krop, MD, PhD, as they discuss recent developments in the field of first-line therapy and maintenance treatment for patients with HER2-positive metastatic breast cancer. 

Released: April 17, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer, Inc.

Target Audience

This activity is intended for oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the role of maintenance therapy in the first line treatment setting for patients with HER2+ MBC and its impact on the therapeutic index, toxicity, treatment de-escalation, and the burden of treatment for patients

  • Discuss the role of endocrine therapy in the treatment of patients with HER2+/HR+ MBC in the first line setting

  • Develop and apply individualized treatment plans and multi-drug management strategies in the maintenance setting for patients with MBC

  • Assess and implement the latest clinical evidence regarding advancements made in the standard of care in the first line setting for patients with HER2+ MBC

Disclosure

Primary Author

Erika Hamilton, MD, FASCO: researcher (paid to institution): AbbVie, Accutar Biotechnology, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, BeOne, Bicycle, Biohaven, BioNTech, Compugen, Cullinan, Daiichi Sankyo, Dantari, Day One Biopharmaceuticals, Duality Biologics, Ellipses, Elucida Oncology, Exelixis, FujiFilm, Genmab, Gilead, H3 Biomedicine, Iambic Therapeutics, Immunogen, Inspirna, InventisBio, Jacobio, Jazz, K-Group Beta, Kind, Lilly, Loxo Oncology, Mabspace, Mabwell, Marengo, MediLink, Merck, Mersana, Novartis, Olema, Orinove, Orum, Pfizer, Pionyr, Prelude, Profound Bio, Regeneron, Relay, Rgenix, Roche/Genentech, SeaGen, Shattuck Labs, Simcha, Stemline, Sutro, Systimmune, Taiho, Tesaro, TheRas, Treadwell, Verastem, Xadcera, Zymeworks; consultant/advisor (paid to institution): Arvinas, AstraZeneca, BeOne, BioNTech, Boehringer Ingelheim, Boundless Bio, Bristol Myers Squibb, Circle, Daiichi Sankyo, Gilead, Halda, Incyclix, IQVIA, Janssen, Jazz, Jefferies, Johnson & Johnson, Lilly, Mersana, Novartis, Pfizer, Precede, Pyxis Oncology, Roche/Genentech, Samsung Bioepis, Shorla, Stemline, Tempus.

Ian Krop, MD, PhD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, EMD Serono, Genentech, Puma, Seagen.